This article is mentioned in:

Introduction

Atypical chronic myeloid leukemia (aCML) is a rare subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with an incidence rate of 1–2 cases for every 100 patients with BCR-ABL1 positive CML (1). In the World Health Organization (WHO) 2008 classification, aCML is characterized as ‘peripheral blood leukocytosis due to increased number of neutrophil and their precursors with prominent dysgranulopoiesis, with absent/minimal monocytosis or basophilia’ (1). In ~40% of patients, aCML develops into acute myeloid leukemia with median survival times ranging between 12 and 29 months. An allogeneic hematopoietic stem cell transplantation (AlloSCT) is the only option to treat aCML, which is associated with poor prognoses (1,2).

Chromosomal abnormalities are exhibited by between 20 and 88% of patients with aCML, with +8, i(17q), or −7/−7q observed most commonly (2). Additionally, SET binding protein 1 (SETBP1) and ethanolamine kinase 1 (ETNK1) mutations are associated with aCML, according to previous studies (3,4). However, no specific recurrent chromosomal or genetic abnormalities have been identified in aCML thus far (5). Conversely, X chromosome abnormalities occur in ~1% of patients with hematological disorders, with i(X)(p10) considered a recurrent chromosomal abnormality in hematological malignancies (6).

In the present study, a case of adult aCML with i(X)(p10) and an additional cytogenetic abnormality appearing 1 year later was described. The cytogenetic abnormalities became undetectable subsequent to the patient undergoing AlloSCT.

Case report

A 40-year-old female was referred to the Tokyo Medical and Dental University Hospital (Tokyo, Japan), due to an annual medical checkup revealing slight leukocytosis and anemia, with a white blood cell count (WBC) of 12×109/l (myelocyte, 2%; metamyelocyote, 6%) and a hemoglobin (Hb) level of 9.4 g/dl. A physical examination demonstrated no remarkable findings. A complete blood count exhibited the following results: WBC of 8.1×109/l (differential: Blast 0%, promyelocyte 0%, myelocyte 0%, metamyelocyte 7%, neutrophil 56%, lymphocyte 19%, monocyte 18%), Hb level of 8.6 g/dl, a platelet count of 230×109/l. The bone marrow morphology revealed 4% blasts, granulocyte proliferation with dysplasia and slight dysplasia in the megakaryocytic lineage identified by May-Giemsa staining with Giemsa and May-Grünwald solutions (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), as presented in Fig. 1.

Figure 1. Bone marrow aspirate smear at point of diagnosis exhibiting hyperplasia of the granulocytic lineage with dysplastic changes. May-Giemsa staining; magnification, ×400.

A G-banded cytogenetic analysis of the bone marrow cells revealed 46, X, i(X)(p10) in all metaphases analyzed, as illustrated in Fig. 2A, and subsequent chromosomal analysis of phytohemagglutinin-stimulated peripheral blood cells revealed the normal female karyotype 46, XX, as demonstrated in Fig. 2B. Fluorescent in situ hybridization (FISH) analysis did not detect the BCR/ABL fusion gene, and the results of the molecular genetic analyses were negative for the Janus kinase 2 (JAK2) V617F mutation, and mutations in granulocyte colony-stimulating factor receptor (CSF3R), SETBP1, and ETNK1.

Figure 2. Partial G-banding karyogram demonstrating the X chromosomes of the bone marrow cells at (A) point of diagnosis and (B) in the phytohemagglutinin-stimulated peripheral blood cells. Arrow indicates i(X)(p10).

The absolute monocyte count of the patient was >1×109/l, and the percentage of monocytes was <10%. Furthermore, the percentage of the neutrophil precursors promyelocytes, myelocytes and metamyelocytes was >10% throughout the clinical course of the patient. Based on these clinical and hematological findings, the diagnosis was aCML.

Initially, the patient did not receive any therapy, but exhibited a rapid increase in WBC to 43×109/l in the 6 months following initial diagnosis, as demonstrated in Fig. 3. Subsequently, hydroxycarbamide therapy was initiated. However, the treatment did not induce an adequate hematological response. Furthermore, an additional cytogenetic abnormality, t(10;17)(p13;q21), was detected in 2/20 bone marrow cells analyzed 1 year following initial diagnosis. Therefore, the patient received AlloSCT from a human leukocyte antigen-matched sibling donor. Prior to this, the patient received 3.2 mg/kg/day intravenous busulfan, in 4 doses, between days 5 and 2 prior to AlloSCT treatment, 30 mg/m2/day fludarabine between days 6 and 2 prior to AlloSCT treatment and total body irradiation using 400 cGy/day in 2 doses on the day of treatment initiation. Graft vs. host disease prophylaxis comprised a continuous infusion of cyclosporine A (2 mg/kg, from 1 day prior to AlloSCT treatment) and a short course of methotrexate (10 mg/m2 on day 1 following AlloCST treatment, and 7 mg/m2 on days 3 and 6 following AlloCST treatment). The patient was successfully engrafted with the donor cells on day 20 of transplantation. Post-transplant cytogenetic analysis revealed a normal male karyotype with full donor chimerism as measured by FISH analysis, showing the XY pattern in >99% of the bone marrow cells.

Figure 3. Clinical course of the patient. Solid black line, white blood cells; solid gray line, hemoglobin; dotted line, immature cells, promyelocytes, myelocytes and metamyelocytes; dashed line, monocytes; FLU, fludarabine; BU, busulfan; TBI, total body irradiation; SCT, stem cell transplantation; BMA, bone marrow aspiration.

Discussion

Although recurrent chromosomal and genetic abnormalities are frequently observed, none are specific to aCML (7). Conversely, a number of genetic mutations have been reported with diverse frequencies: JAK2V617F at 4–8%; CSF3R at <10%; SETBP1 at 25% and ETNK1 at 8.8%. According to previous studies, mutations in SETBP1 or ETNK1 are strongly associated with aCML (3,4,7,8). In the present study, these mutations were not detected by the direct sequencing methods performed in previous studies. Therefore, the present case did not demonstrate the chromosomal abnormalities or genetic mutations previously reported in aCML (3,4,8).

X chromosome abnormalities occur in ~1% of patients with hematological disorders (6). At present, 26 cases with well-characterized i(X)(p10) have been reported, as demonstrated in Table I (6,9–12). All except one of the patients were female. Although the majority of patients exhibited myeloid malignancies, the present study is the first case of a patient with aCML exhibiting i(X)(p10) to be reported to date. It is notable that i(X)(p10) has been demonstrated to be the sole chromosomal abnormality or the abnormality in a stem line in ~50% of previously published studies (6), which suggests that it may serve an initial or primary role in leukemogenesis. However, detailed clinical courses of patients with i(X)(p10) have not been investigated to date. The patient of the present study exhibited i(X)(p10) as the sole chromosomal abnormality at the point of diagnosis of aCML, and acquired the additional t(10;17)(p13;q21) abnormality during the subsequent progression of the disease. This clinical course is compatible with the hypothesis that i(X)(p10) may serve a primary role in leukemogenesis. Furthermore, t(10;17)(p13;q21), which is rare recurrent chromosome abnormality in myeloid leukemia (13), is potentially associated with disease progressions such as the additional cytogenetic abnormalities observed in BCR/ABL-1 positive CML.

Table I. Previously published cases of hematological malignancies with i(X)(p10).

Table I.

Previously published cases of hematological malignancies with i(X)(p10).

Patient	Age	Gender	Disease	Karyotype	(Refs.)
1	74	F	AML	47,X,i(X)(p10),+i(X)(p10)/48,idem,+8/48,idem,+20	(18)
2	79	F	AML	47,X,i(X)(p10),+i(X)(p10)	(19)
3	76	F	MDS	46,X,i(X)(p10)	(20)
4	32	F	CML	47,XX,t(9;22)(q34;q11),+22,47,X,i(X)(p10), t(9;22),+22,48,X,i(X)(p10),+i(X)(p10),t(9;22),+22	(21)
5	26	F	HL	81-85,XX,-X,i(X)(p10),del(1)(p21),+i(2)(p10)x2, del(3)(q21),del(4)(q?25),i(4)(p10),i(4)(q10),+5,-6,-7,del(7)(q32), i(7)(q10),del(9)(q21q31),der(12)t (3;12)(q21;q22), −13,-13,-15,+16,del(17)(p11),-18,-18,-20,add(20)(q13), −22,-22,-22,i(22)(q10),+mar	(22)
6	75	F	CMML	46,X,i(X)(p10)/46,idem,del(20)(q11q13)	(23)
7	65	F	ALL	47,X,i(X)(p10),add(2)(p?),add(14)(q?),-19,+22,+r/47, idem,del(6)(q?),add(16) (q24)	(24)
8	33	M	ALL	46,X,+i(X)(p10),-Y/46,idem,del(17)(p12p13)/46,idem, del(7)(q32q36),del(17)	(25)
9	18	F	HL	59-83,XXX,-X,i(X)(p10),-1,+2,add(2)(q37)x3,+3,-6, del(7)(q12q22),-8,del(8) (q24),-9,-10,-11,-11,del(11)(q12q13), +12,-13,-13,-14,-15,-16,-17,-17,-18, add(20)(q13), +del(20)(q11q13),-21,+4mar	(26)
10	50	F	CML	46,X,i(X)(p10),t(9;22)(q34;q11),i(17) (q10)/50,idem,+1,+8,+13,+19	(27)
11	3	F	ALL	48,XX,+i(X)(p10),+21c	(28)
12	?	F	CMML	46,X,i(X)(p10)	(29)
13	74	F	AML	46, X, i(X)(p10) [5]/46, XX [7]	(30)
14	62	F	MDS	46,X,i(X)(p10)	(6)
15	62	F	AML	46,X,i(X)(p10)
16	17	F	ALL	45,X,-X,r(20)/46,X,i(X)(p10),r(20)
17	73	F	MDS	46,X,i(X)(p10),del(5)(q13q33)
18	32	F	AML	47-50,XX,+i(X)(p10)x2,+8,+9
19	49	F	MDS	46,X,i(X)(p10)
20	76	F	MDS	46,X,i(X)(p10) or del(X)(q24)?c
21	80	F	MDS	46,X,i(X)(p10)
22	38	F	MDS	46,X,i(X)(p10)
23	10	F	ALL	52, XX, i(X)(p10), +4, −7, ins(7;?)(q22;?), t(10;21)(q22;q22), +14, +der(15)t(9;15)(q12;p11.2), +21, +21, mar	(9)
24	68	F	t-AML	46, XX, del(20)(q11) [5]/45, X, i(X)(p10), −7, del(20)(q11) [20]	(10)
25	?	F	AML	46, XX, inv(3)(q21;q26) [1]/45, idem, −7 [11]/45, idem, i(X)(p10), −1 [8]	(11)
26	?	F	CMML	46, X, i(X)(p10)	(12)
27	40	F	aCML	46, XX, i(X)(p10)	Present case

[i] F, female; M, male; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma: CMML, chronic myelomonocytic leukemia; ALL, acute lymphoblastic leukemia; t-AML, therapy-related AML; aCML, atypical CML.

Similar characteristics have been observed for patients exhibiting i(X)(p10) and idic(X)(q13), which is the most common X chromosome-related abnormality with ~30 cases reported (14). This abnormality occurs in females of advanced age (range, 55–87 years) with myeloid malignancies, including aCML, and is often observed as the sole abnormality (15). There are also similar structural abnormalities of the X chromosome in i(X)(p10) and idic(X)(q13) mutations, with the break points at the centromere and Xq13, respectively (6). Based on the clinical and cytogenetic similarities, it is hypothesized that the mutations may share a common mechanism for leukemogenesis. In this regard, previous studies have revealed that the gene dosage effect due to the simultaneous gain of Xp and loss of Xq may serve a crucial role for idic(X)(q13), which does not result in formation of a fusion gene (6,14). Notably, the loss of Xq by idic(X)(q13) and i(X)(p10) results in the deletion of the X-inactive specific transcript (XIST) gene located at Xq13.2. XIST transcribes the long non-coding RNA XIST. The transcribed long non-coding RNA spreads along the X chromosome and serves an important role in the initiation of X inactivation in female cells. Additionally, there is considerable evidence that XIST RNA serves other important functions in the differentiation, proliferation and genome maintenance of human cells. Furthermore, loss of XIST RNA expression has been found in female breast, ovarian and cervical cancer cell lines, thus implicating the dysregulation of XIST in oncogenesis (16). Notably, a previous study demonstrated that the deletion of XIST in the hematopoietic cells in mice results in the development of MDS/MPN with 100% penetrance (17). Thus, a loss of XIST may serve a crucial role in the leukemogenesis of idic(X)(q13) or i(X)(p10) (6,14). Additional genetic and molecular analyses of i(X)(p10) and idic(X)(q13) in patients with MDS/MPN are required to establish the association of a loss of XIST with MDS/MPN in humans.

References